NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Liberator Medical Holdings, Inc. (NYSE: LBMH) investors concerning the proposed acquisition of the company by C. R. Bard, Inc. for approximately $181 million.
The investigation concerns whether the company’s board of directors violated their fiduciary duties by failing to maximize stockholder value. Under the terms of the proposed transaction, Liberator Medical’s stockholders will receive $3.35 in cash for each Liberator Medical share they own.
However, at least one analyst set a target price of $8.00 per Liberator Medical share.
If you purchased Liberator Medical securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.
